REVA's Mission - Stents that Fade Away

Coronary artery disease is currently treated by the placement of a metal stent that serves as a permanent scaffold for the vessel. However, it is now generally believed that a stent's purpose is fully served upon vessel healing. The REVA Bioresorbable Coronary Stent is designed to act as a temporary scaffold during the healing process. Once the vessel has healed, the stent is designed to resorb, leaving the patient free from a permanent implant.

A bioresorbable stent may eliminate concerns regarding incomplete healing and late-stage thrombosis in stent patients, as well as reduce the need for long-term medication.

No Compromise Performance

The non-deforming nature of REVA's Slide & Lock design results in a stent with exceptional strength, flexibility and conformability. It also allows for standard balloon deployment so physicians will not be asked to make changes in their current clinical practice.  

REVA's proprietary bioresorbable polymer, a tyrosine-derived polycarbonate developed at Rutgers University, breaks down benignly and is cleared for the body. It also doubles as a drug-delivery matrix with complete drug release from the polymer.

Visible Using Current and Future Imaging Technologies

The REVA stent is inherently radiopaque, so it is visible by X-ray fluoroscopy, today's most common form of clinical imaging.

In addition, the polymer stent may be more suitable for magnetic resonance imaging (MRI) and computed tomography (CT) imaging, paving the way for less invasive diagnostic and clinical imaging in the future.

Expanding the Treatment of Coronary Artery Disease

Today, bioresorbable stents offer the promise of a "just right" treatment option -- a stent that will treat a patients underlying disease for only as long as necessary, and then fade away, returning the vessel to its natural state.

In the future, a short duration stent combined with a drug to treat vulnerable plaque may provide the ultimate solution for proactively treating coronary artery disease.

By delivering today's and tomorrow's pharmaceutical agents, the REVA Bioresorbable Coronary Stent may ultimately expand the treatment of coronary artery disease.